CD86 and myocardial infarction: DMOG treatment increased the ratio of CXCR4-EGFP+ CD11b+/CD206+ to CD11b+/CD86+ cells by 2.6-fold, suggesting an improved fine-tuning of reparative M2-like CD206+ compared to inflammatory CD86+ cells in the ischemic heart associated with (3) reduced apoptotic cell death, increased neovascularization, reduced scar size, and (4) an improved heart function after MI (Fig. 7).